Page 125 | Certara

Case Study

Dose Optimization Using Population PK for an Orphan Drug

RAPALIMUS® Tablets (sirolimus) is Nobelpharma’s orphan drug developed from an oral medication that is sold…

CertaraNovember 17, 2021

Blog

Industry Metrics for CDISC Controlled Terminology

Sergiy Sirichenko summarizes industry metrics across many studies and sponsors to produce an overall picture…

CertaraNovember 17, 2021

Press Coverage

Leveraging real-world data to meet payers’ needs

CertaraNovember 15, 2021

Press Coverage

Drug Discovery World: The Value of Scientific Intelligence in Drug Discovery

CertaraNovember 9, 2021

Conference

PHUSE EU Connect

–

CertaraNovember 9, 2021

Announcement

Certara Launches Fellowship Program in Africa for Applied Pharmacometrics Training

PRINCETON, N.J.— November 8, 2021 -- Certara, Inc, a global leader in biosimulation, today announced…

CertaraNovember 8, 2021

Blog

Developing Targeted Covalent Inhibitor Drugs: 3 Key Considerations

Traditional mechanisms of drug action rely on the reversible, noncovalent interaction of a ligand with…

CertaraNovember 5, 2021

White Paper

The Importance of Collecting Race/Ethnicity Information in Clinical Trials for Biologics – A Clinical Pharmacology Perspective

CertaraNovember 2, 2021

Case Study

Defining path-to-market strategy through a data-driven and scientific approach

How Certara supported a gene therapy manufacturer by using a selection of gateway and value…

CertaraOctober 28, 2021

Press Release

Certara’s Simcyp™ COVID-19 Vaccine Model Wins R&D 100 Award

Biosimulation tool to conduct ‘what-if’ scenarios with virtual patients recognized in Software/Services category PRINCETON, NJ…

CertaraOctober 25, 2021